- Home
- ACT vs BLTE Comparison
ACT vs BLTE Comparison
Compare ACT & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACT | BLTE |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.0B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACT | BLTE |
|---|---|---|
| Price | $49.19 | $161.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $44.25 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 305.7K | 153.2K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 3.43 | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $1,235,827,000.00 | N/A |
| Revenue This Year | $4.06 | N/A |
| Revenue Next Year | $2.33 | $492.11 |
| P/E Ratio | $20.30 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $34.64 | $62.18 |
| 52 Week High | $50.56 | $200.00 |
Technical Indicators
Market Signals| Indicator | ACT | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 61.57 | 51.24 |
| Support Level | $41.97 | $158.32 |
| Resistance Level | N/A | $172.02 |
| Average True Range (ATR) | 0.88 | 6.82 |
| MACD | -0.08 | -0.74 |
| Stochastic Oscillator | 69.91 | 27.85 |
Price Performance
Historical ComparisonAbout ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.